Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Galapagos Starts Phase 2A Study with GLPG0974 in Ulcerative Colitis

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
Study will deliver topline results early 2014.

Galapagos NV has announced the start of the first Phase 2 clinical study with GLPG0974. This is the third compound from Galapagos' pipeline to enter Phase 2 studies, and its first drug for patients with gastro-intestinal inflammation.

GLPG0974 presents a novel mode of action for the treatment of ulcerative colitis, a debilitating inflammatory bowel disease.

The efficacy and safety of GLPG0974 will be tested in a four-week study with 45 patients and will deliver topline results early 2014.

As a potent inhibitor of FFA2, oral treatment with GLPG0974 aims to reduce migration of neutrophils into the gastro-intestinal tract. Excessive influx of this type of white blood cells damages the bowel tissue and causes chronic inflammation in ulcerative colitis.

The start of the Phase 2 Proof-of-Concept study follows the excellent Phase 1 results with GLPG0974. In healthy volunteers, 2 weeks of once- or twice daily oral dosing was well-tolerated and safe up to the highest doses tested.

A sustained suppression of biomarkers for neutrophil activation demonstrated the desired pharmacodynamic activity.

"We are very excited about the start of the Phase 2 study with GLPG0974. We discovered the role of the FFA2 target in inflammatory diseases, and we developed GLPG0974 as a drug to inhibit FFA2. With this clinical program, we expand our scope from rheumatology to gastroenterology," said Dr Piet Wigerinck, CSO of Galapagos.

Dr Wigerinck continued, "GLPG0974 is the first FFA2 antagonist being evaluated clinically, and we are looking forward to the results in ulcerative colitis patients. If the drug shows efficacy in these patients, this will be an important step, as there is currently no cure for this disease. We expect to report the results of the study in early 2014."

Details of the Phase 2A clinical study
The clinical Proof-of-Concept Phase 2 trial for GLPG0974 will involve 45 patients with mild to moderate ulcerative colitis. The aim is to evaluate the efficacy, effects on selected biomarkers, safety and tolerability and pharmacokinetics of GLPG0974 in this patient population.

Patients with mild to moderate disease will receive either 200 mg of GLPG0974 twice-daily or placebo (2:1 ratio), for a period of four weeks.

This randomized, double-blind, placebo-controlled study will recruit patients in multiple sites in 4 countries: Belgium, Latvia, Czech Republic and Slovakia.

Galapagos has already received approvals to start the trial in Belgium, with patient recruitment starting this month. The trial is anticipated to complete by year end and deliver top line data by Q1 2014.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Initiates a Phase 2a Study with GLPG1690
Company has announced that it has initiated a phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients.
Thursday, April 07, 2016
Galapagos Achieves Clinical Proof-of-Mechanism Milestone in GSK Alliance
The company announced that investigational medicine GLPG0778, which is part of its immuno- inflammatory alliance with GlaxoSmithKline, has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers.
Monday, December 19, 2011
Galapagos Receives €2.7 Million Grant for Antiviral Drug Discovery
The antiviral programs focus on blocking the activity of a protein in the human body that is essential for a number of important pathogenic viruses to carry out their own reproduction.
Friday, February 18, 2011
Galapagos and University of Bristol Enter Drug Discovery Collaboration in Chronic Pain
BioFocus will provide hit-to-lead and lead optimization services for a €3.3 million drug discovery program at the University of Bristol.
Friday, July 16, 2010
Galapagos and Roche Expand COPD Alliance
Partners increase the number of antibody targets in the alliance.
Tuesday, May 11, 2010
Galapagos Initiates Nanocort® Phase II Clinical Trial for Multiple Sclerosis
A single administration of Nanocort will be compared to the standard steroid treatment of three methylprednisolone infusions to evaluate Nanocort in treating MS.
Tuesday, November 24, 2009
Galapagos Reveals Key Drug Target for Alzheimer's Disease
The data presented in Science article describes how GPR3 was identified in human cells using Galapagos' platform.
Friday, February 13, 2009
Galapagos Awarded €4.4 M Grant for Rheumatoid Arthritis Drug Development
The award has been granted for a three-year project aims to accelerate Galapagos' rheumatoid arthritis programs through clinical Proof of Concept in man.
Thursday, January 17, 2008
Scientific News
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
IU Research Reveals Link between Molecular Mechanisms in Prostate Cancer and Ewing's sarcoma
Researchers at IU have suggested that the molecular mechanism that triggers the rare disease Ewing's sarcoma could act as a potential new direction for the treatment of more than half of patients with prostate cancer.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Advances in Alzheimer’s Research
Researchers show how a diseased vertebrate brain can naturally react to Alzheimer’s pathology by forming more neurons.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Alzheimer’s-Linked Protein May Play Role in Schizophrenia
Researchers suggests a protein linked to cognitive decline in Alzheimer's also plays a role in genetic predisposition to schizophrenia.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos